EANS-News: SYGNIS Pharma AG / SYGNIS announces six months results of fiscal year 2011/2012

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

6-month report

Heidelberg (euro adhoc) - SYGNIS announces six months results of
fiscal year 2011/2012

• Capital increase of EUR6.2 million successfully completed
• AX200: results of the AXIS 2 trial by the end of 2011 and
strengthened patent position in H1
• KIBRA: substantial progress of the compound-screening and first
patents granted in Europe and the USA

Heidelberg, November 14, 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its
financial results for the second quarter and the first half of the
fiscal year 2011/2012 ended September 30, 2011.

Financials

• The net loss in the second quarter decreased to EUR-2.0 million (EUR-3.0
million Q2 2010/2011). The net loss for the first half of the fiscal year
2011/2012 amounted to EUR-3.3 million (EUR-5.3 million first half
2010/2011).
• Total operating expenses for the first half were down at EUR4.3 million
(EUR5.6 million H1 2010/2011). Financial result was EUR0.8 million (EUR0.0
million H1 2010/2011).
• Cash including marketable securities amounted to EUR8.1 million as of
September 30, 2011 (EUR11.2 million H1 2010/2011).
• In mid August 2011 SYGNIS completed a capital increase. At the end of the
subscription period, 3,076,623 new shares have been subscribed and
correspondingly the share capital increased from EUR13,752,881 to
EUR16,829,504. As a result, the Company received gross proceeds of EUR6.2
million.

Operational summary

• On 8 August 2011, SYGNIS completed the patient enrolment for the AXIS 2
Study when the last patient was successfully recruited. 328 patients were
treated in eight European countries as part of the study, which tested the
efficacy of AX200 for the treatment of acute stroke.
• In September 2011 the European Patent Office provided two notices
regarding their imminent intention to issue two additional AX200-patents.
The respective patent applications cover the use of AX200 for the acute
and chronic stage of a stroke.
• The patent situation for the KIBRA project has also been improved. In
September 2011 SYGNIS filed new patent applications, which include new
pharmacological pathways to KIBRA.

Significant events after the balance sheet date

On 3 November 2011, SYGNIS reported the completion of treatment for
the AXIS 2 Study. All of the required patient investigations have
now been completed in order to allow the finalization of data
collection and the evaluation of the study data.

Outlook

SYGNIS confirms its earlier expectations of a net loss and a
liquidity outflow of around EUR8-9 million for the current 2011/2012
fiscal year. The Company is financed approximately until the end of
calendar year 2012.

The key operational focus for the upcoming weeks is the analysis of
the AXIS 2 Study data. As planned, results are expected to be
reported by the end of calendar year 2011. Dependent on these
results, the Company will then evaluate the options for further
development and marketing of AX200. Possibilities include
continuing development by the Company itself or through
out-licensing to external parties. In addition, SYGNIS will
consider developing AX200 in cooperation with a partner.

SYGNIS expects first results of its screening activities of the
KIBRA project at the end of the 2011 calendar year. The identified
drug candidates should enable SYGNIS to either enter into a
research partnership or further develop the compounds with its
own resources.

In addition the Company continues to evaluate opportunities to extend its
product pipeline through partnerships or strategic transactions.

|Key financial figures for the second quarter of fiscal year |
|2011/2012 ended September 30, 2011 and corresponding figures (IFRS)|
|Numbers in million euros |Q2 2011/2012 |Q2 2010/2011 |
|Revenues |0.0 |0.0 |
|Total expenses |2.1 |3.1 |
|EBIT |-2.1 |-3.0 |
|Net results for the period |-2.0 |-3.0 |
|Intangible assets |20.5 |21.8 |
|Liquidity at end of quarter |8.1 |11.2 |
|Equity |19.4 |25.0 |
|(equity ratio in %) |(59) |(65) |
|Long-term financial liabilities |8.0 |8.0 |
|Operating Cash Flow |-2.5 |-2.0 |

|Key figures for the first six months of fiscal year 2011/12 ended |
|September 30, 2011 and comparables (IFRS) |
|Numbers in million euros |H1 2011/12 |H1 2010/11 |
|Revenues |0.2 |0.1 |
|Total expenses |4.3 |5.6 |
|EBIT |-4.2 |-5.4 |
|Net results for the period |-3.3 |-5.3 |
|Operating cash flow |-4.5 |-4.3 |

The report on the second quarter which ended on September 30, 2011 is available
at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical
company listed in the Prime Standard of the Frankfurt Stock Exchange. The

Company is focused on the research and development of innovative
therapies for the treatment of disorders of the Central Nervous
System. SYGNIS´ core projects are currently Acute Stroke for which
SYGNIS´ lead clinical programme is AX200, as well as the
preclinical KIBRA-project for the treatment of different forms of
dementia. All these disorders are characterized by the fact that,
as the disease progresses, nerve cells are damaged and die.
Although there is great medical demand, there are currently no or
only inadequate treatment options available. Furthermore, a key
element of the sustainable value creation of the Company is the
expansion of the product pipeline, which will be secured through its
own developments as well as in-licensing and acquisitions.

For further information please contact:

SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

Media-Contact:
Julia Phillips
FTI Consulting
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English